Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240591 | 0.89 | NPC1 (0.54) | HDAC1HDAC8NPC1RAB9AHSD17B3 | |
| SCHEMBL2916728 | 0.88 | NPC1 (0.45) | HDAC1HDAC8NPC1RAB9AHSD17B3 | |
| SCHEMBL2925517 | 0.88 | NPC1 (0.45) | HDAC1HDAC8NPC1RAB9AHSD17B3 | |
| SCHEMBL5509133 | 0.86 | HDAC1 (0.62) | HDAC1HDAC8NPC1RAB9APTPN1 | |
| SCHEMBL3673275 | 0.85 | NPC1 (0.42) | HDAC1HDAC8NPC1RAB9AHSD17B3 | |
| SCHEMBL13525526 | 0.85 | NPC1 (0.42) | HDAC1HDAC8NPC1RAB9AHSD17B3 | |
| SCHEMBL2763202 | 0.85 | NPC1 (0.42) | HDAC1HDAC8NPC1RAB9AHSD17B3 | |
| SCHEMBL1502488 | 0.85 | NPC1 (0.42) | HDAC1HDAC8NPC1RAB9AHSD17B3 | |
| SCHEMBL10471481 | 0.84 | NPC1 (0.53) | HDAC1HDAC8NPC1RAB9AHSD17B3 | |
| SCHEMBL3671755 | 0.83 | MAPT (0.47) | HDAC1HDAC8NPC1RAB9AHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247699-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(CYCLOPROPANECARBONYL)PHENYL]-2-METHYL-PROPANENITRILE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20170369440-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(CYCLOPROPANECARBONYL)PHENYL]-2-METHYL-PROPANENITRILE | EUROAPI GERMANY GMBH (DE) | 2017-12-28 | — | — | US | disclosed |
| WO-2016116555-A1 | Process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| US-8269033-B2 | Process for carbonylating phenylalkyl derivatives by means of carbon monoxide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2261207-A1 | Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives | Aventisub II Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261208-A1 | Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives | Aventisub II Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-1776330-B1 | METHOD FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-09-01 | — | — | EP | disclosed |
| US-20100069661-A1 | PROCESS FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-1953142-A1 | Process for the preparation of antihistaminic 4-diphenylmethyl piperidine derivatives | Aventis Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070161814-A1 | PROCESS FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20020007085-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010031895-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL DOW PHARMACEUTICALS INC. | 2001-10-18 | — | — | US | disclosed |
| US-20010021791-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-09-13 | — | — | US | disclosed |
| US-20010020114-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-09-06 | — | — | US | disclosed |
| US-20010018521-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-08-30 | — | — | US | disclosed |
| US-6242606-B1 | REACTING A A,A-DIMETHYLPHENYLACETIC ACID AMIDE WITH A W-HALO COMPOUND PRODUCES W'-HALO-A-KETO-A,A-DIMETHYLPHENYLACETIC ACID AMIDE AND REACTING IT WITH A PIPERIDINE COMPOUND; 2-(4-(4-CHLORO-BUTYRYL)-PHENYL)-2-METHY-PROPIONIC ACID | MERRELL PHARMACEUTICALS INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010000038-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | CHATTEM INC. | 2001-03-15 | — | — | US | disclosed |
| US-6147216-A | Intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0705245-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000480-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161814-A1 | PROCESS FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | CBR3, CBR1, CYP2E1 | HDAC1 3300/4885HDAC8 4845/4885NPC1 811/4885 |
| US-20010000038-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | HDAC1 295/4885HDAC8 1206/4885NPC1 2412/4885 |
| US-20010020114-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | HDAC1 1552/4885HDAC8 2705/4885NPC1 2390/4885 |
| US-20010021791-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | HDAC1 1142/4885HDAC8 2582/4885NPC1 1689/4885 |
| US-20010031895-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH4, HRH3 | HDAC1 1222/4885HDAC8 2684/4885NPC1 1692/4885 |
| US-20010018521-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | HDAC1 959/4885HDAC8 2216/4885NPC1 2104/4885 |
| US-20100069661-A1 | PROCESS FOR CARBONYLATING PHENYLALKYL DERIVATIVES BY MEANS OF CARBON MONOXIDE | CBR3, CBR1, CYP2E1 | HDAC1 3300/4885HDAC8 4845/4885NPC1 811/4885 |
| US-20020007085-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | HDAC1 1164/4885HDAC8 2636/4885NPC1 1740/4885 |
| US-20170369440-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(CYCLOPROPANECARBONYL)PHENYL]-2-METHYL-PROPANENITRILE | CYP4B1, CYP3A4, CYP4F2 | HDAC1 4256/4885HDAC8 4529/4885NPC1 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.